source
- Longeveron’s pediatric heart stem-cell trial misses primary endpoint, prompting cost cutsLongeveron reported that its phase 2b Elpis II trial of the stem-cell product laromestrocel in infants with hypoplastic left heart syndrome failed to meet its primary efficacy endpoint. The study…
- Experts discuss wet AMD treatment limits and need for longer lasting therapiesIn a recent episode of the Denatured podcast, Professor Philip Jacob Rosenfeld of the University of Miami and Wesley Jackson, chief science officer at Valitor, joined host Jennifer C. Smith-Parker…